Boston Scientific Gross Margin 2010-2024 | BSX
Current and historical gross margin for Boston Scientific (BSX) over the last 10 years. The current gross profit margin for Boston Scientific as of June 30, 2024 is %.
| Boston Scientific Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2024-06-30 | $15.23B | $10.50B | 68.97% |
| 2024-03-31 | $14.71B | $10.19B | 69.31% |
| 2023-12-31 | $14.24B | $9.90B | 69.49% |
| 2023-09-30 | $13.76B | $9.55B | 69.40% |
| 2023-06-30 | $13.40B | $9.31B | 69.49% |
| 2023-03-31 | $13.05B | $9.00B | 69.02% |
| 2022-12-31 | $12.68B | $8.73B | 68.81% |
| 2022-09-30 | $12.57B | $8.65B | 68.83% |
| 2022-06-30 | $12.33B | $8.49B | 68.87% |
| 2022-03-31 | $12.16B | $8.39B | 68.99% |
| 2021-12-31 | $11.89B | $8.18B | 68.78% |
| 2021-09-30 | $11.47B | $7.73B | 67.41% |
| 2021-06-30 | $11.20B | $7.49B | 66.89% |
| 2021-03-31 | $10.12B | $6.57B | 64.90% |
| 2020-12-31 | $9.91B | $6.45B | 65.05% |
| 2020-09-30 | $10.11B | $6.79B | 67.19% |
| 2020-06-30 | $10.16B | $6.93B | 68.25% |
| 2020-03-31 | $10.79B | $7.59B | 70.40% |
| 2019-12-31 | $10.74B | $7.62B | 70.97% |
| 2019-09-30 | $10.39B | $7.40B | 71.18% |
| 2019-06-30 | $10.08B | $7.19B | 71.32% |
| 2019-03-31 | $9.94B | $7.07B | 71.11% |
| 2018-12-31 | $9.82B | $7.01B | 71.36% |
| 2018-09-30 | $9.67B | $6.91B | 71.49% |
| 2018-06-30 | $9.50B | $6.78B | 71.35% |
| 2018-03-31 | $9.27B | $6.65B | 71.78% |
| 2017-12-31 | $9.05B | $6.46B | 71.34% |
| 2017-09-30 | $8.83B | $6.29B | 71.27% |
| 2017-06-30 | $8.71B | $6.22B | 71.38% |
| 2017-03-31 | $8.58B | $6.08B | 70.86% |
| 2016-12-31 | $8.39B | $5.96B | 71.09% |
| 2016-09-30 | $8.17B | $5.79B | 70.88% |
| 2016-06-30 | $7.96B | $5.63B | 70.78% |
| 2016-03-31 | $7.67B | $5.45B | 70.99% |
| 2015-12-31 | $7.48B | $5.30B | 70.94% |
| 2015-09-30 | $7.39B | $5.23B | 70.77% |
| 2015-06-30 | $7.34B | $5.17B | 70.45% |
| 2015-03-31 | $7.37B | $5.18B | 70.26% |
| 2014-12-31 | $7.38B | $5.17B | 70.05% |
| 2014-09-30 | $7.33B | $5.13B | 69.91% |
| 2014-06-30 | $7.22B | $5.05B | 70.00% |
| 2014-03-31 | $7.16B | $5.02B | 70.19% |
| 2013-12-31 | $7.14B | $4.97B | 69.56% |
| 2013-09-30 | $7.13B | $4.93B | 69.12% |
| 2013-06-30 | $7.13B | $4.88B | 68.45% |
| 2013-03-31 | $7.14B | $4.85B | 67.86% |
| 2012-12-31 | $7.25B | $4.90B | 67.60% |
| 2012-09-30 | $7.28B | $4.85B | 66.65% |
| 2012-06-30 | $7.42B | $4.87B | 65.63% |
| 2012-03-31 | $7.56B | $4.90B | 64.84% |
| 2011-12-31 | $7.62B | $4.96B | 65.11% |
| 2011-09-30 | $7.78B | $5.12B | 65.82% |
| 2011-06-30 | $7.82B | $5.22B | 66.73% |
| 2011-03-31 | $7.77B | $5.20B | 66.97% |
| 2010-12-31 | $7.81B | $5.21B | 66.71% |
| 2010-09-30 | $7.88B | $5.23B | 66.38% |
| 2010-06-30 | $7.99B | $5.34B | 66.77% |
| 2010-03-31 | $8.14B | $5.51B | 67.66% |
| 2009-12-31 | $8.19B | $5.61B | 68.54% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $123.274B | $14.240B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $198.609B | 25.65 |
| Stryker (SYK) | United States | $139.112B | 32.51 |
| Medtronic (MDT) | Ireland | $114.744B | 17.07 |
| EssilorLuxottica (ESLOY) | France | $106.116B | 0.00 |
| Haleon (HLN) | United Kingdom | $47.707B | 34.87 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.203B | 0.00 |
| ResMed (RMD) | United States | $35.702B | 31.43 |
| Koninklijke Philips (PHG) | Netherlands | $29.054B | 22.08 |
| Terumo (TRUMY) | Japan | $28.562B | 40.34 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.656B | 13.63 |
| Baxter (BAX) | United States | $19.774B | 13.41 |
| Insulet (PODD) | United States | $16.665B | 70.11 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.531B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.604B | 31.82 |
| Demant (WILYY) | Denmark | $9.197B | 0.00 |
| BellRing Brands (BRBR) | United States | $7.682B | 32.48 |
| Lantheus Holdings (LNTH) | United States | $7.537B | 18.09 |
| ICU Medical (ICUI) | United States | $4.428B | 42.25 |
| TG Therapeutics (TGTX) | United States | $3.914B | 41.44 |
| Haemonetics (HAE) | United States | $3.842B | 19.01 |
| Neogen (NEOG) | United States | $3.799B | 39.84 |
| Perrigo (PRGO) | Ireland | $3.788B | 11.97 |
| GN Store Nord (GNNDY) | Denmark | $3.691B | 22.23 |
| Prestige Consumer Healthcare (PBH) | United States | $3.663B | 18.25 |
| Envista Holdings (NVST) | United States | $3.324B | 17.73 |
| QuidelOrtho (QDEL) | United States | $3.108B | 19.59 |
| Agios Pharmaceuticals (AGIO) | United States | $2.696B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.230B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $2.192B | 36.79 |
| LeMaitre Vascular (LMAT) | United States | $2.026B | 54.00 |
| AdaptHealth (AHCO) | United States | $1.520B | 10.97 |
| InMode (INMD) | Israel | $1.490B | 9.49 |
| Warby Parker (WRBY) | United States | $1.483B | 0.00 |
| AtriCure (ATRC) | United States | $1.403B | 0.00 |
| Owens & Minor (OMI) | United States | $1.237B | 9.55 |
| BioLife Solutions (BLFS) | United States | $1.187B | 0.00 |
| Verano Holdings (VRNOF) | United States | $1.110B | 0.00 |
| Evolus (EOLS) | United States | $1.037B | 0.00 |
| PetIQ (PETQ) | United States | $0.919B | 23.30 |
| Phibro Animal Health (PAHC) | United States | $0.908B | 18.83 |
| National Vision Holdings (EYE) | United States | $0.862B | 27.40 |
| Cresco Labs (CRLBF) | United States | $0.805B | 0.00 |
| Quanterix (QTRX) | United States | $0.594B | 0.00 |
| Surmodics (SRDX) | United States | $0.562B | 119.39 |
| ZimVie (ZIMV) | United States | $0.468B | 43.49 |
| VAREX IMAGING (VREX) | United States | $0.445B | 13.43 |
| Valneva SE (VALN) | France | $0.419B | 0.00 |
| Jin Medical (ZJYL) | China | $0.411B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.401B | 0.00 |
| Cerus (CERS) | United States | $0.339B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.335B | 0.00 |
| Biote (BTMD) | United States | $0.331B | 15.27 |
| OraSure Technologies (OSUR) | United States | $0.324B | 8.37 |
| Aurora Cannabis (ACB) | Canada | $0.315B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.291B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.290B | 31.08 |
| Zynex (ZYXI) | United States | $0.264B | 46.28 |
| Utah Medical Products (UTMD) | United States | $0.236B | 15.70 |
| Omeros (OMER) | United States | $0.234B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.221B | 0.00 |
| MacroGenics (MGNX) | United States | $0.213B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.192B | 0.00 |
| High Tide (HITI) | Canada | $0.172B | 71.33 |
| Capricor Therapeutics (CAPR) | United States | $0.162B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.154B | 20.74 |
| Brainsway (BWAY) | Israel | $0.137B | 163.80 |
| TriSalus Life Sciences (TLSI) | United States | $0.135B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.129B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.122B | 0.00 |
| Veru (VERU) | United States | $0.117B | 0.00 |
| Fonar (FONR) | United States | $0.110B | 11.15 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.101B | 24.70 |
| Jushi Holdings (JUSHF) | United States | $0.100B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.087B | 0.00 |
| InterCure (INCR) | Israel | $0.085B | 14.31 |
| Cytosorbents (CTSO) | United States | $0.077B | 0.00 |
| Safety Shot (SHOT) | United States | $0.076B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.076B | 0.00 |
| Modular Medical (MODD) | United States | $0.074B | 0.00 |
| MariMed (MRMD) | United States | $0.065B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.055B | 3.62 |
| Exagen (XGN) | United States | $0.050B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.041B | 0.00 |
| Apyx Medical (APYX) | United States | $0.038B | 0.00 |
| ImmuCell (ICCC) | United States | $0.028B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.026B | 0.00 |
| Nephros (NEPH) | United States | $0.019B | 0.00 |
| Flora Growth (FLGC) | United States | $0.019B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.016B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.016B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Agape ATP (ATPC) | $0.007B | 0.00 | |
| Sharps Technology (STSS) | United States | $0.007B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.000B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 20.48 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |